Technical Analysis for URGN - UroGen Pharma Ltd.

Grade Last Price % Change Price Change
grade C 32.78 6.67% 2.05
URGN closed up 6.67 percent on Friday, December 6, 2019, on 68 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long-Term Intermediate-Term Short-Term
Strong Flat Up Up
See historical URGN trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Hammer Candlestick Bullish 6.67%
Slingshot Bullish Bullish Swing Setup 6.67%
Multiple of Ten Bullish Other 6.67%
Wide Bands Range Expansion 6.67%
Overbought Stochastic Strength 6.67%
Wide Bands Range Expansion 5.13%
Overbought Stochastic Strength 5.13%

Older signals for URGN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Medicine Biopharmaceutical Cancer Surgery Chemotherapy Antineoplastic Drugs Overactive Bladder Non Muscle Invasive Bladder Cancer Interstitial Cystitis

Is URGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 55.49
52 Week Low 20.72
Average Volume 181,896
200-Day Moving Average 32.80
50-Day Moving Average 25.06
20-Day Moving Average 28.93
10-Day Moving Average 31.19
Average True Range 1.42
ADX 49.87
+DI 33.17
-DI 12.82
Chandelier Exit (Long, 3 ATRs ) 28.63
Chandelier Exit (Short, 3 ATRs ) 26.86
Upper Bollinger Band 34.23
Lower Bollinger Band 23.64
Percent B (%b) 0.86
BandWidth 36.59
MACD Line 1.94
MACD Signal Line 1.71
MACD Histogram 0.2288
Fundamentals Value
Market Cap 426.44 Million
Num Shares 13 Million
EPS -1.67
Price-to-Earnings (P/E) Ratio -19.63
Price-to-Sales 20.42
Price-to-Book 4.84
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 35.60
Resistance 3 (R3) 35.32 34.11 35.13
Resistance 2 (R2) 34.11 33.39 34.25 34.97
Resistance 1 (R1) 33.44 32.94 33.78 33.72 34.82
Pivot Point 32.23 32.23 32.39 32.37 32.23
Support 1 (S1) 31.56 31.51 31.90 31.84 30.74
Support 2 (S2) 30.35 31.06 30.49 30.59
Support 3 (S3) 29.68 30.35 30.43
Support 4 (S4) 29.96